Login / Signup

In vitro biological evaluation of a novel folic acid-targeted receptor quantum dot-β-cyclodextrin carrier for C-2028 unsymmetrical bisacridine in the treatment of human lung and prostate cancers.

Joanna PilchAgnieszka PotęgaPatrycja KowalikAgata KowalczykPiotr BujakArtur KasprzakEwa PaluszkiewiczAnna Maria Nowicka
Published in: Pharmacological reports : PR (2024)
-β-CD-FA) for drug delivery in cancer treatment. Nanoplatforms increased the amount of delivered compounds and demonstrated high suitability.
Keyphrases
  • drug delivery
  • cancer therapy
  • prostate cancer
  • benign prostatic hyperplasia
  • ionic liquid
  • mass spectrometry
  • binding protein
  • childhood cancer